Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

IL13-PE38QQR

Known as: IL 13-PE38QQR, IL-13 Toxin, Interleukin-13 PE38QQR Immunotoxin 
A recombinant chimeric protein with potent antitumor activity. Cintredekin besudotox is composed of interleukin-13 (IL13), a pleiotropic… Expand
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ExotoxinsInterleukin-13

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Convection-enhanced delivery (CED) of cintredekin besudotox (CB) was compared with Gliadel wafers (GW) in adult patients with… Expand
  • table 1
  • table 2
  • table 3
  • table 3
  • figure 1
Highly Cited
2010
Highly Cited
2010
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics
Restricting the cytotoxicity of anticancer agents by targeting receptors exclusively expressed on tumor cells is critical when… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Highly Cited
2007
Highly Cited
2007
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
PURPOSE Glioblastoma multiforme (GBM) is a devastating brain tumor with a median survival of 6 months after recurrence… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Highly Cited
2007
Highly Cited
2007
CONVECTION‐ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN‐13‐PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS: PHASE 1 STUDY OF FINAL…
OBJECTIVECintredekin besudotox (CB), a recombinant cytotoxin consisting of interleukin-13 and truncated Pseudomonas exotoxin… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2007
Highly Cited
2007
INTRACEREBRAL INFUSATE DISTRIBUTION BY CONVECTION‐ENHANCED DELIVERY IN HUMANS WITH MALIGNANT GLIOMAS: DESCRIPTIVE EFFECTS OF TARGET ANATOMY AND CATHETER POSITIONING
OBJECTIVE Convection-enhanced delivery (CED) holds tremendous potential for drug delivery to the brain. However, little is known… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Highly Cited
2007
Highly Cited
2007
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.
Convection-enhanced delivery (CED) is a novel drug delivery technique that uses positive infusion pressure to deliver therapeutic… Expand
Highly Cited
2007
Highly Cited
2007
Convection-enhanced delivery of cintredekin besudotox (interleukin-13- PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas
 
Highly Cited
2005
Highly Cited
2005
Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.
OBJECT Convection-enhanced delivery (CED) is a novel method for delivering therapeutic agents to infiltrative brain tumor cells… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2004
2004
Interstitial Infusion of IL13-PE38QQR in the Rat Brain Stem
Interstitial infusion of IL13-PE38QQR, a tumor specific, chimeric cytotoxin, into the rat brain stem was performed in an effort… Expand
  • figure 1
  • figure 2
  • figure 3
Highly Cited
1996
Highly Cited
1996
Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
We have previously shown that human renal cell carcinoma (RCC) cells express large numbers of interleukin-13 receptors (IL-13R… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE